Silicon Image Introduces 225 MHz HDMI v1.3 PHY IC and Soft Link IP Core for Consumer Electronics Applications
New Solution Offers Lower Cost and Faster Time-To-Market for HDMI v1.3 Transmitter Implementations
Silicon Image Introduces 225 MHz HDMI v1.3 PHY IC and Soft Link IP Core for Consumer Electronics Applications
Silicon Image, Inc. (NASDAQ:SIMG), a leader in semiconductors and intellectual property for the secure distribution, presentation and storage of high-definition content, today announced its 225 MHz HDMI™ version 1.3 PHY solution, consisting of the SiI9204 HDMI v1.3 transmitter PHY semiconductor and companion HDMI v1.3 link layer intellectual property (IP) core for use in consumer electronics and high-end mobile device applications. This latest offering complements the Silicon Image family of HDMI v1.3 transmitters which include stand-alone discrete semiconductors, PHY semiconductors for use with link layer IP cores and full HDMI v1.3 link and PHY IP cores.
Today, integrated circuit (IC) providers have the option of either using external discrete HDMI chips or fully integrating HDMI functionality into their consumer electronics ICs. Silicon Image now offers an HDMI v1.3 transmitter solution that provides the benefits of both approaches, with a lower bill-of-materials (BOM) cost compared to discrete IC implementations and faster time-to-market compared to a fully integrated system-on-a-chip (SoC) solution. In addition, Silicon Image’s HDMI v1.3 transmitter technology is a silicon-proven, high-volume solution that has shipped in more than 10 million HDMI v1.3 transmitter chips since 2007.
“HDMI version 1.3 is already the standard for digital TVs and is now becoming prevalent in high-definition digital set-top-box and Blu-ray Disc™ player implementations,” stated Ron Richter, director of business development at Silicon Image, Inc. “Silicon Image’s PHY IC and link IP core solution delivers the high-quality video and audio capabilities of HDMI v1.3 without the engineering challenges associated with an SoC analog integration.”
Key features of Silicon Image's SiI9204 transmitter PHY include:
- 225 MHz HDMI v1.3 support for Deep Color applications
- SiI9002 compatibility mode (for those who use SiI9002 today)
- Low power at high resolutions & frame rates (<90mW @ 1080p/60fps 12 bits/pixel)
- Low power down current (<10µA)
- Integrated CEC hardware support
- Display Data Channel (DDC) support
- Can support High Bit-Rate audio and x.v.Color with full featured SoCs
- 40-pin 6X6mm QFN package
- Competitive pricing for link IP core licensing and SiI9204 chip
The SiI9204 IC, with built-in Consumer Electronics Control (CEC), is ideal for consumer applications such as digital set-top-boxes, personal video recorders, Blu-ray Disc players, game consoles, high-definition (HD) camcorders and high-end mobile devices. The link layer IP core, designed to be integrated into an SoC, can be quickly targeted to any foundry or process, delivering a key time-to-market advantage when compared to a fully integrated mixed-signal solution.
Planned availability for the SiI9204 transmitter PHY is Q1 2009 and the accompanying link layer IP will be available for integration in Q4 2008. More information on the Silicon Image transmitter IC and IP core solutions can be found at www.siliconimage.com . Companies, engineers and developers interested in additional information should contact Ron Richter at Tel: 1-408-962-4259 or via email at ron.richter@siliconimage.com .
About Silicon Image, Inc.
Silicon Image, Inc. is a leading provider of semiconductor and intellectual property products for the secure distribution, presentation and storage of high-definition content. With a rich history of technology innovation that includes creating industry standards such as DVI and HDMI, the company’s solutions facilitate the use of digital content amongst consumer electronics, personal computer (PC) and storage devices, with the goal to securely deliver digital content anytime, anywhere and on any device. Founded in 1995, the company is headquartered in Sunnyvale, California, with regional engineering and sales offices in China, Germany, Japan, Korea, Taiwan and the United Kingdom. For more information, please visit www.siliconimage.com .
Forward-looking Statements
This news release contains forward-looking statements within the meaning of federal securities laws and regulations, including, but not limited to, statements regarding the anticipated performance, cost and time-to-market benefits of Silicon Image’s HDMI v1.3 PHY and IP core solution. These forward-looking statements involve risks and uncertainties, including those described from time to time in Silicon Image’s filings with the Securities and Exchange Commission (SEC), that could cause the actual results to differ materially from those anticipated by these forward-looking statements. Silicon Image assumes no obligation to update any forward-looking statement.
Silicon Image and the Silicon Image logo are trademarks, registered trademarks or service marks of Silicon Image, Inc. in the United States and/or other countries. HDMI is a trademark or registered trademark of HDMI Licensing, LLC in the United States and/or other countries. All other trademarks and registered trademarks are the property of their respective owners in the Unites States and/or other countries.
Contact:
Silicon Image, Inc.
Gabriele Collier, 408-616-4088
gabriele.collier@siliconimage.com
or
Ogilvy
Public Relations for Silicon Image, Inc.
Ian Yellin, 415-677-2714
ian.yellin@ogilvypr.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press release
Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to exi
IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press release
IonQ and Einride will collaborate to develop quantum solutions for fleet routing, logistics optimization, and supply chain solutionsIonQ’s investment will grow its European presence and reinforce commitment to building a quantum economy in Sweden and the European market IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global frei
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press release
Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current s
NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 21:24:00 CEST | Press release
NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates
Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 21:08:00 CEST | Press release
As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom